Navigation Links
A new anti diabetic drug on the anvil

India leads the top 10 countries estimated to have the highest number of diabetics in 2000 and 2030, with China and the US following closely. Type II Diabetes, one of the most common chronic diseases globally, is fast gaining // epidemic proportions throughout the world, with pathological manifestations including obesity, hypertension, hyperlipidemia and cardiovascular diseases. Since diabetes causes significant morbidity and mortality due to long-term micro and macro vascular complications, new drugs are required to combat it.

Glenmark Pharmaceuticals has recently filed for Phase I clinical trials for GRC 8200, its leading DPP-IV inhibitor compound, with the Medicines and Healthcare Products Regulatory Agency [MHRA] in the U.K. The dipeptidylpeptidase IV [DPP-IV] target is associated with glucose dependent insulin secretion and peripheral insulin resistance. While no DPP-IV inhibitor has been approved for marketing till date, among the scientific community DPP-IV inhibitors are expected to offer significant potential for being the therapy of choice, once approved.

The Phase I study will be conducted by Parexel U.K., a leading global CRO. The Phase I study is expected to be completed in February 2006 and will be conducted using single and multiple oral doses on healthy volunteers. The objective of this study is to assess the safety and bioavailability of GRC 8200 in humans. Pre-clinical studies have demonstrated GRC 8200 to be many times more potent than competing DPP-IV inhibitors. The compound is highly bioavailable and safe, displaying significant reduction in glucose excursion on oral glucose challenge. Pre-clinical studies have also demonstrated that GRC 8200 has the potential of being a long-acting compound with high selectivity to the DPP-IV target over DPP-II, VIII and IX.

Glenn Saldanha, Managing Director and CEO of Glenmark, states “We have a very aggressive timeline and hope to be the fourth to market with GRC 8200 in the DPP-IV class. We expect GRC 8200 to be launched on the US market in 2010.”
'"/>




Related medicine news :

1. Gastrointestinal ills more common in diabetics
2. Pollution- hazardous for diabetics
3. New treatment for diabetics
4. Breast screening among diabetic women
5. Needle free future for diabetics
6. Care for footwear not required diabetic patients
7. Nightlights could ward diabetic blindness
8. Gene variant foretells diabetic neuropathy
9. Protein in diabetic neuropathy treatment
10. New target for antidiabetic agents identified
11. Study links diabetics to increased risk of urinary tract infections
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology: